Christopher John Chermansky

Christopher John Chermansky

Auto-generated profile, based on publicly available information

Christopher John Chermansky

Department of Urology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Journal of Urology
Verified
Journal Article
Closed access
Holly E RichterHolly E Richter
Holly E Richter
CAC.L. Amundsen
C.L. Amundsen
SES.W. Erickson
S.W. Erickson
JJJ.E. Jelovsek
J.E. Jelovsek
YKY. Komesu
Y. Komesu
NNNichd Pelvic Floor Disorders Network
Nichd Pelvic Floor Disorders Network
We sought to identify clinical and demographic characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation therapies. We analyzed data from the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation versus BoTulinum Toxin Assessment) trial. Baseline participant characteristics and clinical variables were associated with 2 definitions of treatment response, including 1) a reduction in mean daily urgency incontinence episodes during 6 months and 2) a 50% or greater decrease in urgency incontinence episodes across 6 months. The OAB-S (Overactive Bladder-Satisfaction) questionnaire was used to assess satisfaction. A greater reduction in mean daily urgency incontinence episodes was associated with higher HUI-3 (Health Utility Index-3) scores in the onabotulinumtoxinA group and higher baseline incontinence episodes (each p <0.001) in the 2 groups. Increased age was associated with a lesser decrease in incontinence episodes in the 2 groups (p <0.001). Increasing body mass index (adjusted OR 0.82/5 points, 95% CI 0.70-0.96) was associated with reduced achievement of a 50% or greater decrease in incontinence episodes after each treatment. Greater age (adjusted OR 0.44/10 years, 95% CI 0.30-0.65) and a higher functional comorbidity index (adjusted OR 0.84/1 point, 95% CI 0.71-0.99) were associated with reduced achievement of a 50% or greater decrease in urgency incontinence episodes in the onabotulinumtoxinA group only (p <0.001 and 0.041, respectively). In the onabotulinumtoxinA group increased satisfaction was noted with higher HUI-3 score (p = 0.002) but there was less satisfaction with higher age (p = 0.001). Older women with multiple comorbidities, and decreased functional and health related quality of life had decreased treatment response and satisfaction with onabotulinumtoxinA compared to sacral neuromodulation for refractory urgency incontinence.

1 October 2016 in Autonomic Neuroscience
Verified
Journal Article
Closed access
CCChristopher J. Chermansky
Christopher J. Chermansky
PMPamela A. Moalli
Pamela A. Moalli

15 September 2015 in Current Bladder Dysfunction Reports
Verified
Journal Article
Closed access
PDF file
BKBrian T. Kadow
Brian T. Kadow
PTPradeep Tyagi
Pradeep Tyagi
CCChristopher J. Chermansky
Christopher J. Chermansky

10 August 2018 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
ETEi‐Ichiro Takaoka
Ei‐Ichiro Takaoka
MKMasahiro Kurobe
Masahiro Kurobe
HOHiroki Okada
Hiroki Okada
STShun Takai
Shun Takai
TSTakahisa Suzuki
Takahisa Suzuki
CCChristopher J. Chermansky
Christopher J. Chermansky

10 December 2019 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
CCChristopher Chermansky
Christopher Chermansky
BSBrigitte Schürch
Brigitte Schürch
Mohammad Sajjad Rahnama'iMohammad Sajjad Rahnama'i
Mohammad Sajjad Rahnama'i
MAMarcio A. Averbeck
Marcio A. Averbeck
SMSachin Malde
Sachin Malde
ASArun Sahai
Arun Sahai

1 July 2021 in Urology
Verified
Journal Article
Closed access
TMTara Nikonow Morgan
Tara Nikonow Morgan
NPNatalie Pace
Natalie Pace
AMAnand Mohapatra
Anand Mohapatra
DRDianxu Ren
Dianxu Ren
GKGregory Kunkel
Gregory Kunkel
CCChristopher J. Chermansky
Christopher J. Chermansky